Log in to search using one of your social media accounts:

 

IsoRay Announces "Long-term PSA Outcomes in a Single Institution, Prospective Randomized Cesium-131 / Iodine-125 Permanent Prostate Brachytherapy Trial" Poster Presentation at 2017 Annual American Society for Radiation Oncology (ASTRO) Conference
9-Year Study Demonstrates Durable Positive Outcomes and Statistically Identical Results of Cesium-131 RICHLAND, Wash., Sept. 25, 2017 -- (Healthcare Sales & Marketing Network) -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator ... Devices, Oncology IsoRay, brachytherapy, radiotherapy, cesium, iodine, prostate cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 25, 2017 Category: Pharmaceuticals Source Type: news

7 medtech stories we missed this week: Sept. 8, 2017
[Image from unsplash.com]From BrainScope’s pediatric traumatic brain injury assessment device to EOS Imaging releasing new surgery planning software, here are seven medtech stories we missed this week but thought were still worth a mention. 1. BrainScope to develop pediatric traumatic brain injury assessment device BrainScope announced in a Sept. 7 press release that it will immediately start creating a pediatric capability for its BrainScope One medical neurotechnology. The technology is an FDA-cleared handheld medical device that is designed to assess the full spectrum of traumatic brain injury. The company sa...
Source: Mass Device - September 8, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Cardiac Assist Devices Cardiovascular Clinical Trials Diagnostics Food & Drug Administration (FDA) Imaging mHealth (Mobile Health) Neurological Regulatory/Compliance Research & Development Spinal AliveCor Bonesupport Bra Source Type: news

No Difference in Toxicity for 6 - , 2 - Fraction HDR in Prostate Cancer
Urinary, sexual toxicity similar with 6 - , 2 - fraction high - dose - rate brachytherapy regimen (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 7, 2017 Category: Cancer & Oncology Tags: Oncology, Radiology, Urology, Journal, Source Type: news

C4 gets new FDA clearance for Sirius MRI marker
Image-guided technology developer C4 Imaging announced that the U.S. Food and...Read more on AuntMinnie.comRelated Reading: C4 touts MRI-guided prostate brachytherapy study C4 raises $1.3M for multimodality marker C4 Imaging nets 510(k) clearance for MRI marker (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 6, 2017 Category: Radiology Source Type: news

iCad wins Chinese approval for Xoft Axxent balloon applicators
iCad (NSDQ:ICAD) said today its Xoft Axxent balloon applicators have been cleared by the China Food & Drug Administration for treating early-stage breast cancer. The Nashua, N.H.-based company’s Xoft Axxent balloon applicators are part of its Xoft Axxent electronic brachytherapy system designed to perform intraoperative radiation therapy in early-stage breast cancer patients who meet specific selection criteria. The balloon applicator is used to deliver a single dose of radiation to the lumpectomy cavity to target cancer cells directly and limit exposure to health surrounding tissue, iCad said. “The Xo...
Source: Mass Device - August 30, 2017 Category: Medical Devices Authors: Fink Densford Tags: Oncology Regulatory/Compliance Women's Health iCad Inc. Source Type: news

ASTRO supports US Nuclear Regulatory Commission final rule
(American Society for Radiation Oncology) The American Society for Radiation Oncology (ASTRO) applauds the United States Nuclear Regulatory Commission for yesterday's announcement of a final rule that updates the definition of medical events for permanent implant brachytherapy and protects patients' access to this treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 18, 2017 Category: International Medicine & Public Health Source Type: news

7 medtech stories we missed this week: August 11, 2017
[Image from unsplash.com]From Xtant Medical’s 510(k) extension to Varian Medical’s distribution deal, here are seven medtech stories we missed this week but thought were still worth a mention. 1. FDA extends Xtant Medical’s 510(k) for Calix C spinal implant Xtant Medical announced in an Aug. 9 press release that the FDA has cleared its product line extensions for the Calix-C cervical inter body cages. The clearance allows for two larger footprints to be added for use with allograft. The Calix-C Cervical Interbody Spacer is designed for spinal fusion procedures at level one in patients who are skeletally m...
Source: Mass Device - August 11, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Cardiovascular Clinical Trials Food & Drug Administration (FDA) Oncology Regulatory/Compliance Spinal Surgical Apifix Cardiac Science Hip Innovation Life Spine Inc. MedTech Pentax Medical Varian Medical Systems Xtant M Source Type: news

Varian Medical Systems Signs Brachytherapy Applicator Distribution Agreement with Bionix Radiation Therapy
PALO ALTO, Calif., Aug. 9, 2017 -- (Healthcare Sales & Marketing Network) -- Varian Medical Systems (NYSE: VAR) today announced it has signed an agreement with Bionix® Radiation Therapy to distribute Bionix brachytherapy applicators. Varian will marke... Devices, Oncology, Distribution Varian Medical Systems, Bionix Radiation Therapy, brachytherapy applicators (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 9, 2017 Category: Pharmaceuticals Source Type: news

IsoRay touts prostate cancer treatment data
Medical isotope developer IsoRay is highlighting data that show that brachytherapy...Read more on AuntMinnie.comRelated Reading: FDA responds to IsoRay's GammaTile 510(k) Court approves IsoRay class-action settlement IsoRay agrees to settle shareholder lawsuit IsoRay revenue falls, net loss edges up in Q4 IsoRay touts brain brachytherapy study results (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 1, 2017 Category: Radiology Source Type: news

Right-Sided Metastatic CRC Benefits From Adding SIRT to Chemotherapy
Patients with colorectal cancer that has metastasized to the liver derive a significant benefit from selective internal radiation therapy (SIRT) combined with chemotherapy if their primary tumor is a right-sided tumor, but not if it is a left-sided primary tumor. (Source: CancerNetwork)
Source: CancerNetwork - July 10, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Colorectal Cancer Gastrointestinal Cancer News Source Type: news

IsoRay Announces Appointment of Mark Austin as Controller, Principal Accounting and Financial Officer
Public Accounting Background RICHLAND, Wash., July 7, 2017 -- (Healthcare Sales & Marketing Network) -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatme... Devices, Oncology, Personnel IsoRay, brachytherapy, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 7, 2017 Category: Pharmaceuticals Source Type: news

Medical News Today: Colorectal cancer: Adding SIRT to chemotherapy boosts survival
For patients with advanced colorectal cancer, new research suggests that adding selective internal radiation therapy to chemotherapy may prolong survival. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 7, 2017 Category: Consumer Health News Tags: Colorectal Cancer Source Type: news

FDA responds to IsoRay's GammaTile 510(k)
The U.S. Food and Drug Administration (FDA) has issued a response to medical...Read more on AuntMinnie.comRelated Reading: Court approves IsoRay class-action settlement IsoRay agrees to settle shareholder lawsuit IsoRay revenue falls, net loss edges up in Q4 IsoRay touts brain brachytherapy study results IsoRay revenue edges higher, but net loss grows (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 6, 2017 Category: Radiology Source Type: news

FDA requests more info on IsoRay ’ s GammaTile
IsoRay (NYSE:ISR) said today that the FDA requested additional data on the company’s pending 510(k) application for its GammaTile radiation therapy system. The Richland, Wash.-based company’s GammaTile is a radiation system using Cesium-131 radiation seeds embedded in a collagen ’tile’ which is designed to be placed in surgical margins at the time of surgery. “This is a good outcome for the novel GammaTile product. With the completion of additional testing anticipated by the end of 2017, we project potential 510(k) clearance of the GammaTile product in the 1st half of 2018 which would all...
Source: Mass Device - July 6, 2017 Category: Medical Devices Authors: Fink Densford Tags: Food & Drug Administration (FDA) Oncology IsoRay Source Type: news

IsoRay Receives FDA Response to 510(k) Application for GammaTile(TM)
Additional Testing for GammaTile™ Planned for Completion by Year-End 2017 RICHLAND, Wash., July 6, 2017 -- (Healthcare Sales & Marketing Network) -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medi... Devices, Oncology, FDA IsoRay, GammaTile, radiotherapy, brachytherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 6, 2017 Category: Pharmaceuticals Source Type: news

New Analysis Reveals First-Line Treatment Data on SIR-Spheres(R) Y-90 Resin Microspheres for Patients with Liver Metastases from Right-Sided Primary Colon Cancer
SIRFLOX and FOXFIRE Global findings suggest that adding liver-directed Selective Internal Radiation Therapy (SIRT) to standard first-line chemotherapy may improve overall survival in metastatic colorectal cancer (mCRC) patients with right-sided primary tum... Devices, Oncology Sirtex Medical, SIR-Spheres, Y-90 resin, microspheres, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 3, 2017 Category: Pharmaceuticals Source Type: news

Robot-assisted Implantation of Brachytherapy Catheters Promising in Bladder Cancer Robot-assisted Implantation of Brachytherapy Catheters Promising in Bladder Cancer
Robot-assisted laparoscopic (RAL) implantation of brachytherapy catheters (BTC) is a minimally invasive alternative to open retropubic surgery, researchers from the Netherlands report.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - June 27, 2017 Category: Surgery Tags: Hematology-Oncology News Source Type: news

IsoRay touts another ‘ 100% ’ study
IsoRay (NYSE:ISR) today released data from a study of its Cesium-131 brachytherapy for treating patients with large brain metastases, touting a 100% freedom from local progression. Results from the study were published in the International Journal of Radiation Oncology, Biology, Physics, the Richland, Wash.-based company said. In the study, researchers assessed the impact of low-dose rate Cesium-131 brachytherapy on local control and radionecrosis in 42 patients treated for a total of 46 large brain metastases. Patients in the trial underwent surgical resection with intra-operative palcement of standard Cesium-131 see...
Source: Mass Device - June 20, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Oncology IsoRay Source Type: news

Elekta points to study of older lung cancer patients
Radiation oncology vendor Elekta is highlighting research that found stereotactic...Read more on AuntMinnie.comRelated Reading: Elekta debuts MR-linac radiation therapy system at ESTRO Varian, Elekta settle patent dispute Elekta nabs Canadian Medical Device License Elekta gets FDA clearance for brachytherapy applicator Elekta to support ASTRO safety initiative (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 15, 2017 Category: Radiology Source Type: news

Prostate cancer brachytherapy: Can I pass radiation to others?
(Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - June 3, 2017 Category: Consumer Health News Source Type: news

Eckert & Ziegler to buy German firms
Isotope technology firm Eckert & Ziegler beat out the competition to acquire...Read more on AuntMinnie.comRelated Reading: Eckert & Ziegler reports loss in Q4 Eckert & Ziegler to produce pancreatic cancer agent Eckert & Ziegler warns of lower profit in 2013 report Eckert & Ziegler posts modest sales uptick Eckert & Ziegler acquires brachytherapy firm (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 24, 2017 Category: Radiology Source Type: news

Brachytherapy: Alternative to Surgery in Penile Cancer? Brachytherapy: Alternative to Surgery in Penile Cancer?
The largest study to date of the use of brachytherapy in penile cancer showed high rates of survival and allowed men to avoid surgery.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Prostate Cancer Patients Satisfed With HDR Brachytherapy Prostate Cancer Patients Satisfed With HDR Brachytherapy
A single outpatient treatment with high-dose-rate (HDR) brachytherapy for prostate cancer was associated with low toxicity and high quality of life.Medscape Medical News (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - May 9, 2017 Category: Radiology Tags: Hematology-Oncology News Source Type: news

ESTRO: Survival in Pancreatic Ca Rises with RT Dose
(MedPage Today) -- Also: cartoons during RT, brachytherapy for penile cancer (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - May 9, 2017 Category: Gastroenterology Source Type: news

Elekta debuts MR-linac radiation therapy system at ESTRO
Radiation oncology vendor Elekta is using this week's annual meeting of the...Read more on AuntMinnie.comRelated Reading: Varian, Elekta settle patent dispute Elekta nabs Canadian Medical Device License Elekta gets FDA clearance for brachytherapy applicator Elekta to support ASTRO safety initiative Varian claims favorable ruling in Elekta patent suit (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 8, 2017 Category: Radiology Source Type: news

Brachytherapy rather than surgery is a good option for cancer of the penis
(European Society for Radiotherapy and Oncology (ESTRO)) Results from the largest group of men treated for cancer of the penis by a single institution have shown that treatment with brachytherapy is a good option that can be used instead of surgery in many cases. The study, presented at the 36th annual congress of the European SocieTy for Radiotherapy& Oncology, is important because penile cancer is extremely rare and so it is difficult to gather enough evidence to show that one type of treatment is better than another. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 7, 2017 Category: Global & Universal Source Type: news

Medical News Today: Advanced liver cancer: Selective internal radiation therapy safer than sorafenib
A phase III trial of selective internal radiation therapy for hepatocellular carcinoma has found the treatment is safer and just as effective as sorafenib. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 25, 2017 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Varian, Elekta settle patent dispute
Radiation oncology firm Varian Medical Systems announced it has reached a confidential...Read more on AuntMinnie.comRelated Reading: Elekta nabs Canadian Medical Device License Brazil hospital uses Varian's Calypso system Varian wins Chinese contract Elekta gets FDA clearance for brachytherapy applicator Varian completes Imaging Components spin-off Elekta to support ASTRO safety initiative (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 4, 2017 Category: Radiology Source Type: news

Updated Guideline on Brachytherapy in Prostate Cancer Updated Guideline on Brachytherapy in Prostate Cancer
The American Society of Clinical Oncology and Cancer Care Ontario have issued updated guidelines on brachytherapy for prostate cancer patients. (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - March 30, 2017 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Updated Guidelines on Brachytherapy for Prostate Cancer (FREE)
By Joe Elia Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM The American Society of Clinical Oncology and Cancer Care Ontario have issued a joint updated guideline on … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 29, 2017 Category: Primary Care Source Type: news

AccuBoost wins trade grant
Women's health firm AccuBoost has been awarded a trade grant from the Massachusetts...Read more on AuntMinnie.comRelated Reading: AccuBoost signs Baptist Memorial Health Care AccuBoost adds Fla. site AccuBoost lands Minn. customer AccuBoost gets Fla. installation AccuBoost points to study in Brachytherapy (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 28, 2017 Category: Radiology Source Type: news

ASCO and Cancer Care Ontario update guideline on radiation therapy for prostate cancer
(American Society of Clinical Oncology) The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario today issued a joint clinical practice guideline update on brachytherapy (internal radiation) for patients with prostate cancer. The update provides evidence-based recommendations for different patient risk groups, and specifies the most effective forms of brachytherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 28, 2017 Category: Cancer & Oncology Source Type: news

FDA OK's iCAD tomosynthesis software
Computer-aided detection (CAD) developer iCAD said its PowerLook Tomo Detection...Read more on AuntMinnie.comRelated Reading: iCAD hits Xoft milestone iCAD to highlight Xoft clinical results at SABCS iCAD highlights breast cancer studies at RSNA 2016 iCAD taps new CFO iCAD touts brachytherapy research at ASTRO 2016 (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 27, 2017 Category: Radiology Source Type: news

IsoRay Announces Final Court Approval of Class Action Settlement
RICHLAND, Wash., March 9, 2017 -- -- (Healthcare Sales & Marketing Network) -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung,... Devices, Oncology, Litigation IsoRay, brachytherapy, radiotherapy, cesium (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 10, 2017 Category: Pharmaceuticals Source Type: news

Court approves IsoRay class-action settlement
Medical isotope developer IsoRay said a federal court has approved the settlement...Read more on AuntMinnie.comRelated Reading: IsoRay agrees to settle shareholder lawsuit IsoRay revenue falls, net loss edges up in Q4 IsoRay touts brain brachytherapy study results IsoRay revenue edges higher, but net loss grows IsoRay taps new VP of sales, marketing (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 10, 2017 Category: Radiology Source Type: news

iCAD hits Xoft milestone
More than 3,000 early-stage breast cancer patients have been treated with intraoperative...Read more on AuntMinnie.comRelated Reading: iCAD to highlight Xoft clinical results at SABCS iCAD highlights breast cancer studies at RSNA 2016 iCAD taps new CFO iCAD touts brachytherapy research at ASTRO 2016 iCAD president resigns (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 9, 2017 Category: Radiology Source Type: news

iCAD Announces More Than 3,000 Early-Stage Breast Cancer Patients Treated with Intraoperative Radiation Therapy Using the Xoft System
NASHUA, N.H. and MIAMI, March 9, 2017 -- (Healthcare Sales & Marketing Network) -- (Booth #T6) - iCAD, Inc. (ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatmen... Devices, Oncology iCAD , Xoft, IORT, radiotherapy, brachytherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 9, 2017 Category: Pharmaceuticals Source Type: news

Study finds single, escalated dose of brachytherapy radiation may be a safe and effective treatment for localized prostate cancer
Results from a new prospective clinical trial indicate that high-dose-rate (HDR) brachytherapy administered in a single, 19 Gray (Gy) treatment may be a safe and effective alternative to longer courses of HDR treatment for men with localized prostate cancer. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 1, 2017 Category: Science Source Type: news

Single dose of brachytherapy may be an effective treatment for localized prostate cancer
(American Society for Radiation Oncology) Results from a new prospective clinical trial indicate that high-dose-rate (HDR) brachytherapy administered in a single, 19 Gray (Gy) treatment may be a safe and effective alternative to longer courses of HDR treatment for men with localized prostate cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 1, 2017 Category: Global & Universal Source Type: news

Elekta wins Health Canada nod for Leksell Gamma Knife Icon SRS system
Elekta (STO:EKTA B) said today it won Health Canada approval for its Leksell Gamma Knife Icon radiosurgery system. The Stockholm, Sweden-based company touted its Leksell Gamma Knife Icon radiosurgery system as the only SRS system designed specifically for targeting brain tissue. The Icon is the 6th generation version of the radiosurgery system from the Elekta. “Robust clinical evidence from more than one million procedures supports Gamma Knife as the most precise SRS platform in the world. Icon was designed with multiple technology upgrades that enable improved work flow and efficiencies. As part of our ong...
Source: Mass Device - February 28, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Radiosurgery Regulatory/Compliance Elekta AB Source Type: news

Elekta nabs Canadian Medical Device License
Health Canada has issued a Medical Device License (MDL) to radiation oncology...Read more on AuntMinnie.comRelated Reading: Elekta gets FDA clearance for brachytherapy applicator Elekta to support ASTRO safety initiative Varian claims favorable ruling in Elekta patent suit Judge finds in favor of Elekta in dispute with Varian Elekta lands large order from India (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 28, 2017 Category: Radiology Source Type: news

Fewer Skin Side Effects With Accelerated Partial Breast Irradiation Fewer Skin Side Effects With Accelerated Partial Breast Irradiation
Accelerated partial breast irradiation (APBI) with interstitial brachytherapy may be an alternative to whole-breast irradiation (WBI) for some patients, according to five-year results from the GEC-ESTRO trial. (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 22, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Elekta wins FDA 510(k) clearance for Venezia gynecological brachytherapy applicator
Elekta (STO:EKTA B) said today it won FDA 510(k) clearance for its Venezia applicator for gynecological brachytherapy, now cleared for the treatment of advanced-stage cervical cancer. The company’s Venezia device is designed to facilitate pre-defined, consistent needle placement for interstitial brachytherapy and to allow operating clinicians the ability to access tumors that extend outside of the cervix. “There is overwhelming clinical evidence that modern image-guided brachytherapy is an effective treatment modality for cervical cancer. Advanced stage disease, however, often requires an interstitial tech...
Source: Mass Device - February 3, 2017 Category: Medical Equipment Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Oncology Regulatory/Compliance Women's Health Elekta AB Source Type: news

Elekta gets FDA clearance for brachytherapy applicator
Radiation oncology vendor Elekta has received 510(k) clearance from the U.S....Read more on AuntMinnie.comRelated Reading: Elekta to support ASTRO safety initiative Varian claims favorable ruling in Elekta patent suit Judge finds in favor of Elekta in dispute with Varian Elekta lands large order from India Elekta highlights ASTRO MR-linac research (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 2, 2017 Category: Radiology Source Type: news

Brachytherapy Plus EBRT for Intermediate-Risk Prostate Cancer Brachytherapy Plus EBRT for Intermediate-Risk Prostate Cancer
Questions persist about the benefits of combination therapy vs brachytherapy alone, despite findings of a new study, says Dr Gerald Chodak.Medscape Urology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - January 24, 2017 Category: Radiology Tags: Urology Commentary Source Type: news

Stockholm County Council, New Karolinska Solna and Elekta Sign Long-term Collaboration Agreement to Advance Cancer Care
STOCKHOLM, Sweden, Dec 30, 2016 -- (Healthcare Sales & Marketing Network) -- Elekta (EKTA-B.ST), Stockholm's County Council and New Karolinska Solna (NKS) have signed a 13-year collaboration agreement which focuses on innovation, joint research, and educa... Devices, Neurosurgery Elekta, radiation therapy, linear accelerator, brachytherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 30, 2016 Category: Pharmaceuticals Source Type: news

Salutaris lands FDA OK for radionuclide brachytherapy
Ophthalmic medical device developer Salutaris Medical Devices has received...Read more on AuntMinnie.com (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 20, 2016 Category: Radiology Source Type: news

National cancer group recommends Sirtex ’ s microspheres for metastatic colorectal cancer
Sirtex Medical (ASX:SRX) said yesterday that the National Comprehensive Cancer Network has recommended the company’s radioactive microspheres in its Clinical Practice Guidelines in Oncology for colon cancer and rectal cancer. The NCCN panel uniformly agreed that selective internal radiation therapy with yttrium-90 microspheres is an option for patients with metastatic, chemotherapy resistant colorectal cancer. The recommendation was supported by the More retrospective analysis study, which included 600 patients with colorectal cancer. The data suggested that selective internal radiation therapy using Y-90 m...
Source: Mass Device - December 13, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Oncology Sirtex Medical Source Type: news

iCAD to highlight Xoft clinical results at SABCS
Computer-aided detection (CAD) developer iCAD plans to highlight at the upcoming...Read more on AuntMinnie.comRelated Reading: iCAD highlights breast cancer studies at RSNA 2016 iCAD taps new CFO iCAD touts brachytherapy research at ASTRO 2016 iCAD president resigns iCAD shows revenue decline in Q2 (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 7, 2016 Category: Radiology Source Type: news

iCAD highlights breast cancer studies at RSNA 2016
Computer-aided detection (CAD) developer iCAD is touting two studies at RSNA...Read more on AuntMinnie.comRelated Reading: iCAD taps new CFO iCAD touts brachytherapy research at ASTRO 2016 iCAD president resigns iCAD shows revenue decline in Q2 iCAD adds to customer base (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 28, 2016 Category: Radiology Source Type: news